AUSTIN, Texas, April 11, 2018 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that the company has received the 2018 Corporate Innovator Award from the National Kidney Foundation. The award will be presented to Keryx today at the NKF Spring Clinical Meetings in Austin, Texas.

“The Corporate Innovator Award was established to recognize industry partners that advance the field of nephrology by addressing an unmet medical need, or improving upon an existing practice, therapeutic or technology,” said Kevin Longino, CEO, National Kidney Foundation and a kidney transplant patient. “This year, we are recognizing Keryx Biopharmaceuticals for their work in developing innovative medicines for patients living with chronic kidney disease.”

“Keryx is a team of approximately 200 committed people working with passion to advance the care of people living with kidney disease,” said John Neylan, M.D., chief medical officer of Keryx Biopharmaceuticals. “We are honored to be recognized by the National Kidney Foundation with this award.”

About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc., headquartered in Boston, Massachusetts, is focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with kidney disease. The Keryx team consists of approximately 200 committed people working with passion to advance the care of people with this complex disease. This dedication has resulted in two FDA-approved indications for Keryx’s first medicine, Auryxia^®(ferric citrate) tablets. For more information about Keryx, please visit www.keryx.com.